Medpace Raises Outlook On Gains in New Business Awards

Dow Jones
07/22

Medpace raised its full-year outlook after it reported a second-quarter profit that beat analysts' expectations boosted by gains in new business awards.

Medpace shares surged 46% in premarket.

The clinical research company on Monday reported $90.3 million in net income, or $3.10 a share, up from $88.4 million, or $2.75 a share, from the prior year. Analysts expected $2.98 a share.

Medpace reported $603.3 million in revenue, beating Wall Street's expectations of $539 million and up from $528.1 million the year prior. Net new business awards were $620.5 million, up from $551 million in the second quarter of 2024.

The company raised its 2025 earnings per share guidance to $13.76 to $14.53, up from a range of $12.26 to $13.04.

It also increased its revenue forecast to between $2.42 billion and $2.52 billion, which would represent growth of 14.7% to 19.5% from 2024 revenue.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10